On July 29, Eastman Kodak (NYSE: KODK) announced it received a $765 million loan from the U.S. government under the Defense Production Act to manufacture active pharmaceutical ingredients in generic drugs as part of a broader response to the coronavirus pandemic. After the news broke out, investors went into a euphoric buying frenzy. In the span of a single day, Kodak's share jumped nearly 300% and trading of the stock was temporarily halted for a time. Perhaps bizarrely, shares of Kodak are now among the best-performing in any stock sector, with a mouth-watering 614% return year to date.
Considering the stock-shattering jump, investors who didn't buy into the rally may feel like they missed out, and those who did may find it incredibly difficult to keep holding onto profits. Let's take a look at whether the stock has already reached its full potential or whether more growth could be ahead.
Image source: Getty Images.
Source Fool.com